Monthly Oncology Tumor Boards: Systemic Therapy for Metastatic Prostate Cancer

April 26, 2024

Patients with metastatic prostate cancer have many treatment options in both the castration-sensitive and the castration-resistant settings, and new data may impact future options. Learn about the results of recent trials, updates to NCCN Guideline recommendations, and common supportive care needs, so that you can provide optimal management for patients with metastatic prostate cancer.

Target Audience

This activity is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss current options for treatment of metastatic castration-sensitive prostate cancer, including triplet therapy with androgen deprivation therapy, chemotherapy, and novel hormone therapy. 
  • Describe treatment options and how they are selected for patients with metastatic castration-resistant prostate cancer.
  • Identify common supportive care needs and approaches for patients with metastatic prostate cancer.

You may also be interested in

Advances in the Management of Metastatic Castration-Resistant Prostate Cancer: Expert Guidance and Resources for the Interdisciplinary Team
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with metastatic castration-resistant prostate cancer.
NCCN Guidelines® Insights - Prostate Cancer, Version 3.2024
These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence.
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca, GSK, Lantheus, and Novartis. This educational activity is supported by a medical education grant from Exelixis, Inc. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
02/13/2024
Course expires: 
07/07/2024
Event starts: 
04/26/2024 - 2:00pm EDT
Event ends: 
04/26/2024 - 3:00pm EDT
Cost:
$0.00
Part of: 
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care
Add to calendar: 

Benjamin A. Teply, MD
Fred & Pamela Buffett Cancer Center

Jared P. Schober, MD
Fred & Pamela Buffett Cancer Center

Kristen E. Boyle, APRN-NP
Fred & Pamela Buffett Cancer Center

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no financial relationships with ineligible companies to disclose.

Kristen E. Boyle, APRN-NP 
Jared P. Schober, MD 

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Benjamin A. Teply, MD
Bellicum Pharmaceuticals: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Consulting Fee
Exelixis Inc.: Consulting Fee
Pfizer Inc.: Scientific Advisor
QED Pharmaceuticals: Grant/Research Support
sanofi-aventis U.S.: Consulting Fee
SeaGen: Consulting Fee

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-031-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: I00059058; Approval #: 240001128

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

This webinar was presented live one time only on Friday, April 26, 2024, from 2:00 PM – 3:00 PM EDT (UTC -4).
The recorded activity is available here.

 

NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.

To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing